Overview
MOA
Impact
X
Procedure
Guidelines
Resources
Clinical Library
Reimbursement
Grants
Order Cysview
Overview
White vs. Blue Light
Patient Stories
Bladder Cancer Overview
X
Resources
Home
BLC™ with Cysview®
>
News
Health Care Professionals
>
Find a BLC with Cysview Center
X
Cysview LogoHamburger Menu Icon
Menu
Find a BLC with Cysview Center

What Is BLC™ with
Cysview®?

BLC™ with Cysview®

What Is Blue Light
Cystoscopy with 
Cysview®?


BLADDER VIEWED WITH

WHITE LIGHT
VS

BLADDER VIEWED WITH

BLUE LIGHT

Blue Light Cystoscopy (BLC™) with Cysview® is a breakthrough procedure that has been approved by the FDA for detecting bladder cancer.

1 out of 4 patients
Found additional tumors in 1 out of 4
patients.9
24.9%
of patients with ≥1 additional Ta/T1 tumor detected with BLC with Cysview versus white light alone.2

Once Cysview (hexaminolevulinate HCl) is placed in the bladder by the medical staff, it begins to be absorbed by cancerous cells, which then causes them to glow pink under blue light. The vivid, bright pink color helps physicians clearly see and remove bladder cancer tumors.

Benefits of BLC with Cysview

BLC with Cysview has been extensively studied in clinical trials across the U.S., Canada and Europe.4-8 The technology is FDA approved for surgery in the Operating Room (OR) and for your follow-up cystoscopies. Additionally, it is included in both the American Urological Association (AUA) and Society of Urological Oncology (SUO) guidelines for treating non-muscle invasive bladder cancer.

Bladder cancer patients are at a high risk for recurrence and progression into muscle invasive bladder cancer11 — a more aggressive form — due in part to missed tumors and incomplete surgeries. With BLC with Cysview, physicians can perform a more thorough evaluation of the bladder and a more complete resection of the bladder cancer tumor(s). This improvement may lead to making better disease management decisions.8

 BLC with Cysview Patient

How BLC with Cysview Works

Bladder Illustration

1 Cysview solution (less than 2 ounces) is delivered (by medical staff) into the bladder about an hour before your cystoscopy procedure. The procedure will take place before three hours have passed from Cysview being put into your bladder.

Example of white light

2 The physician examines the bladder in the traditional white light.

Example of superior blue light

3 When the doctor switches to blue light, other hard-to-see tumors, that may be present, become more visible.

Important Limitations of Use

BLC with Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.

Talk to your doctor about BLC with Cysview or find a BLC with Cysview provider near you.

Prescribing Information

Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLCTM) as an adjunct to the white light cystoscopy.

Important Safety Information About Cysview® (hexaminolevulinate HCl)

Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer. 

Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain. 

Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. Cysview may fail to detect some malignant lesions. False-positive fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy and recent BCG therapy or intravesical chemotherapy. No specific drug interaction studies have been performed. 

Safety and effectiveness have not been established in pediatric patients. There are no available data on Cysview use in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal. There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition. 

Cysview is approved for use with the KARL D-Light C Photodynamic Diagnostic (PDD) system. For system set up and general information for the safe use of the PDD system, please refer to the KARL STORZ instruction manuals for each of the components. 

Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions.

Photocure Logo

Prescribing Information

Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLCTM) as an adjunct to the white light cystoscopy.

Important Safety Information About Cysview® (hexaminolevulinate HCl)

Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer. 

Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain. 

Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. Cysview may fail to detect some malignant lesions. False-positive fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy and recent BCG therapy or intravesical chemotherapy. No specific drug interaction studies have been performed. 

Safety and effectiveness have not been established in pediatric patients. There are no available data on Cysview use in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal. There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition. 

Cysview is approved for use with the KARL D-Light C Photodynamic Diagnostic (PDD) system. For system set up and general information for the safe use of the PDD system, please refer to the KARL STORZ instruction manuals for each of the components. 

Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions.

Photocure Logo
<  PREV  Home
BACK TO TOP
NEXT  White vs. Blue Light  >